Analyst Reco. Royalty Pharma plc

Equities

RPRX

GB00BMVP7Y09

Real-time Estimate Cboe BZX Other stock markets 19:02:48 29/04/2024 BST			5-day change	1st Jan Change
28.2 ^USD	+0.73%		+1.44%	+0.46%

04-17	Royalty Pharma Maintains Quarterly Dividend at $0.21 per Share, Payable June 14 to Shareholders of Record May 17	MT
04-17	Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Morgan Stanley Lifts Price Target on Royalty Pharma to $46 From $44, Keeps Overweight Rating	04-09	MT
JPMorgan Cuts Price Target on Royalty Pharma to $42 From $45, Keeps Overweight Rating	02-20	MT
Goldman Sachs Cuts Price Target on Royalty Pharma to $50 From $56, Keeps Buy Rating	02-20	MT
Morgan Stanley Cuts Price Target on Royalty Pharma to $46 From $57, Keeps Overweight Rating	12-12	MT
ANALYST RECOMMENDATIONS : Adobe, Amgen, Blackrock, IBM, Ulta Beauty...	12-12
Morgan Stanley Adjusts Price Target on Royalty Pharma to $57 From $54, Maintains Overweight Rating	11-09	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $54 From $53, Maintains Overweight Rating	11/10/23	MT
UBS Adjusts Royalty Pharma Price Target to $41 From $44, Maintains Buy Rating	09/08/23	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $53 From $52, Maintains Overweight Rating	09/08/23	MT
UBS Adjusts Royalty Pharma Price Target to $44 From $48, Maintains Buy Rating	24/07/23	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $52 From $50, Maintains Overweight Rating	10/05/23	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $50 From $48, Maintains Overweight Rating	10/04/23	MT
Fitch Affirms Royalty Pharma plc at 'BBB-'; Outlook Stable	04/04/23	AQ
Bank of England lifts rates by 25 basis points	23/03/23	AN
UBS Adjusts Royalty Pharma's Price Target to $48 From $51, Maintains Buy Rating	16/02/23	MT
Morgan Stanley Cuts Price Target on Royalty Pharma to $51 From $54, Maintains Overweight Rating	06/12/22	MT
UBS Adjusts Royalty Pharma Price Target to $51 From $50, Maintains Buy Rating	09/11/22	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $54 From $51, Maintains Overweight Rating	09/11/22	MT
JPMorgan Chase Adjusts Royalty Pharma's Price Target to $52 From $50, Keeps Overweight Rating	18/10/22	MT
Morgan Stanley Increases Royalty Pharma's Price Target to $51 From $48, Maintains Overweight Rating	08/08/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Royalty Pharma plc

Equities

RPRX

GB00BMVP7Y09

Analyst Reco.

Filters